MindWalk Holdings (HYFT) Non-Current Deferred Tax Liability (2020 - 2026)
MindWalk Holdings (HYFT) posted quarterly Non-Current Deferred Tax Liability of $560990.1 for Q2 2026, up 219.32% year-over-year from $175682.2 in Q2 2025, and up 219.32% quarter-over-quarter from $175682.2 in Q2 2025.
MindWalk Holdings (HYFT) Non-Current Deferred Tax Liability (2020 - 2026) Analysis & Trends
MindWalk Holdings (HYFT) has reported Non-Current Deferred Tax Liability for 7 consecutive years, with $560990.1 the latest figure, recorded in Q2 2026.
- In Q2 2026, Non-Current Deferred Tax Liability rose 219.32% year-over-year to $560990.1; the TTM figure through Apr 2026 stood at $560990.1 (up 219.32% YoY), while the FY2026 annual figure was $560990.1, up 212.58% from the prior year.
- Non-Current Deferred Tax Liability advanced to $560990.1 in Q2 2026 per HYFT's latest filing, from $175682.2 in the prior quarter.
- Across five years, Non-Current Deferred Tax Liability topped out at $6.4 million in Q2 2022 and bottomed at $167653.6 in Q1 2025.
- Historically, Non-Current Deferred Tax Liability has averaged $3.7 million across 5 years, with a median of $5.1 million in 2024.
- Annual changes were most pronounced in 2023 — Non-Current Deferred Tax Liability soared 595.25% — and 2025, when it slumped 96.71%.
- MindWalk Holdings' Non-Current Deferred Tax Liability stood at $5.8 million in 2022, then decreased by 8.88% to $5.3 million in 2023, then slumped by 55.41% to $2.3 million in 2024, then tumbled by 92.52% to $175682.2 in 2025, then jumped by 219.32% to $560990.1 in 2026.
- Business Quant data shows HYFT's Non-Current Deferred Tax Liability at $560990.1 in Q2 2026, $175682.2 in Q2 2025, and $167653.6 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 560,990.13 |
| Apr 30, 2026 | 560,990.13 |
| Apr 30, 2025 | 175,682.17 |
| Apr 30, 2025 | 175,682.17 |
| Jan 31, 2025 | 167,653.59 |
| Jan 31, 2025 | 167,653.59 |
| Oct 31, 2024 | 2.35 Mn |
| Oct 31, 2024 | 2.35 Mn |
| Jul 31, 2024 | 2.47 Mn |
| Jul 31, 2024 | 2.47 Mn |
| Apr 30, 2024 | 3.00 Mn |
| Apr 30, 2024 | 3.00 Mn |
| Jan 31, 2024 | 5.09 Mn |
| Jan 31, 2024 | 5.09 Mn |
| Oct 31, 2023 | 5.27 Mn |
| Oct 31, 2023 | 5.27 Mn |
| Jul 31, 2023 | 5.45 Mn |
| Jul 31, 2023 | 5.45 Mn |
| Apr 30, 2023 | 5.66 Mn |
| Apr 30, 2023 | 5.66 Mn |